NEUROCRINE BIOSCIENCES INC Cost of Revenue
NEUROCRINE BIOSCIENCES INC (NBIX) reported Cost of Revenue of $13.80 million for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-05.
Financial Statements › Expense Statement › Cost of Sales
us-gaap:CostOfGoodsAndServicesSold · last filed 2026-05-05
- NEUROCRINE BIOSCIENCES INC cost of goods and services sold for the quarter ending 2026-03-31 was $13.80M, a 50.00% increase year-over-year.
- NEUROCRINE BIOSCIENCES INC cost of goods and services sold for the quarter ending 2025-12-31 was $17.60M, a 89.25% increase year-over-year.
- NEUROCRINE BIOSCIENCES INC cost of goods and services sold for the quarter ending 2025-09-30 was $14.00M, a 75.00% increase year-over-year.
- NEUROCRINE BIOSCIENCES INC cost of goods and services sold for the quarter ending 2025-06-30 was $11.30M, a 22.83% increase year-over-year.
- NEUROCRINE BIOSCIENCES INC cost of goods and services sold for fiscal 2025 was $52.10M, a 53.24% increase from fiscal 2024.
- NEUROCRINE BIOSCIENCES INC cost of goods and services sold for fiscal 2024 was $34.00M, a 14.36% decline from fiscal 2023.
- NEUROCRINE BIOSCIENCES INC cost of goods and services sold for fiscal 2023 was $39.70M, a 71.12% increase from fiscal 2022.
- NEUROCRINE BIOSCIENCES INC cost of goods and services sold for fiscal 2022 was $23.20M, a 62.24% increase from fiscal 2021.
| Period end | Cost of Goods and Services Sold 3 month | Cost of Goods and Services Sold 3 month as first filed | Cost of Goods and Services Sold 6 month | Cost of Goods and Services Sold 6 month as first filed | Cost of Goods and Services Sold 9 month | Cost of Goods and Services Sold 12 month |
|---|---|---|---|---|---|---|
| 2026-03-31 | $13.80M 10-Q · filed 2026-05-05 | $31.40M derived: sum of 2 quarters · filed 2026-05-05 | $45.40M derived: sum of 3 quarters · filed 2026-05-05 | $56.70M derived: sum of 4 quarters · filed 2026-05-05 | ||
| 2025-12-31 | $17.60M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $31.60M derived: sum of 2 quarters · filed 2026-02-11 | $42.90M derived: sum of 3 quarters · filed 2026-02-11 | $52.10M 10-K · filed 2026-02-11 | ||
| 2025-09-30 | $14.00M 10-Q · filed 2025-10-28 | $25.30M derived: sum of 2 quarters · filed 2025-10-28 | $34.50M 10-Q · filed 2025-10-28 | $43.80M derived: sum of 4 quarters · filed 2026-05-05 | ||
| 2025-06-30 | $11.30M 10-Q · filed 2025-07-30 | $20.50M 10-Q · filed 2025-07-30 | $29.80M derived: sum of 3 quarters · filed 2026-05-05 | $37.80M derived: sum of 4 quarters · filed 2026-05-05 | ||
| 2025-03-31 | $9.20M 10-Q · filed 2026-05-05 | $18.50M derived: sum of 2 quarters · filed 2026-05-05 | $26.50M derived: sum of 3 quarters · filed 2026-05-05 | $35.70M derived: sum of 4 quarters · filed 2026-05-05 | ||
| 2024-12-31 | $9.30M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $17.30M derived: sum of 2 quarters · filed 2026-02-11 | $26.50M derived: sum of 3 quarters · filed 2026-02-11 | $34.00M 10-K · filed 2026-02-11 | ||
| 2024-09-30 | $8.00M 10-Q · filed 2025-10-28 | $17.20M derived: sum of 2 quarters · filed 2025-10-28 | $24.70M 10-Q · filed 2025-10-28 | $33.20M derived: sum of 4 quarters · filed 2026-02-11 | ||
| 2024-06-30 | $9.20M 10-Q · filed 2025-07-30 | $16.70M 10-Q · filed 2025-07-30 | $25.20M derived: sum of 3 quarters · filed 2026-02-11 | $36.40M derived: sum of 4 quarters · filed 2026-02-11 | ||
| 2024-03-31 | $7.50M 10-Q · filed 2025-05-05 | $16.00M derived: sum of 2 quarters · filed 2026-02-11 | $27.20M derived: sum of 3 quarters · filed 2026-02-11 | $38.70M derived: sum of 4 quarters · filed 2026-02-11 | ||
| 2023-12-31 | $8.50M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $19.70M derived: sum of 2 quarters · filed 2026-02-11 | $31.20M derived: sum of 3 quarters · filed 2026-02-11 | $39.70M 10-K · filed 2026-02-11 | ||
| 2023-09-30 | $11.20M 10-Q · filed 2024-10-30 | $22.70M derived: sum of 2 quarters · filed 2024-10-30 | $31.20M 10-Q · filed 2024-10-30 | $38.90M derived: sum of 4 quarters · filed 2025-02-10 | ||
| 2023-06-30 | $11.50M 10-Q · filed 2024-08-01 | $20.00M 10-Q · filed 2024-08-01 | $27.70M derived: sum of 3 quarters · filed 2025-02-10 | $33.80M derived: sum of 4 quarters · filed 2025-02-10 | ||
| 2023-03-31 | $8.50M 10-Q · filed 2024-05-01 | $16.20M derived: sum of 2 quarters · filed 2025-02-10 | $22.30M derived: sum of 3 quarters · filed 2025-02-10 | $27.10M derived: sum of 4 quarters · filed 2025-02-10 | ||
| 2022-12-31 | $7.70M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-10 | $13.80M derived: sum of 2 quarters · filed 2025-02-10 | $18.60M derived: sum of 3 quarters · filed 2025-02-10 | $23.20M 10-K · filed 2025-02-10 | ||
| 2022-09-30 | $6.10M 10-Q · filed 2023-10-31 | $10.90M derived: sum of 2 quarters · filed 2023-10-31 | $15.50M 10-Q · filed 2023-10-31 | $19.60M derived: sum of 4 quarters · filed 2024-02-09 | ||
| 2022-06-30 | $4.80M 10-Q · filed 2023-08-01 | $9.40M 10-Q · filed 2023-08-01 | $13.50M derived: sum of 3 quarters · filed 2024-02-09 | $17.70M derived: sum of 4 quarters · filed 2024-02-09 | ||
| 2022-03-31 | $4.60M 10-Q · filed 2023-05-03 | $8.70M derived: sum of 2 quarters · filed 2024-02-09 | $12.90M derived: sum of 3 quarters · filed 2024-02-09 | $16.00M derived: sum of 4 quarters · filed 2024-02-09 | ||
| 2021-12-31 | $4.10M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-09 | $8.30M derived: sum of 2 quarters · filed 2024-02-09 | $11.40M derived: sum of 3 quarters · filed 2024-02-09 | $14.30M 10-K · filed 2024-02-09 | ||
| 2021-09-30 | $4.20M 10-Q · filed 2022-11-01 | $7.30M derived: sum of 2 quarters · filed 2022-11-01 | $10.20M 10-Q · filed 2022-11-01 | $13.10M derived: sum of 4 quarters · filed 2023-02-09 | ||
| 2021-06-30 | $3.10M 10-Q · filed 2022-08-04 | $6.00M 10-Q · filed 2022-08-04 | $8.90M derived: sum of 3 quarters · filed 2023-02-09 | $11.60M derived: sum of 4 quarters · filed 2023-02-09 | ||
| 2021-03-31 | $2.90M 10-Q · filed 2022-05-04 | $5.80M derived: sum of 2 quarters · filed 2023-02-09 | $8.50M derived: sum of 3 quarters · filed 2023-02-09 | $10.90M derived: sum of 4 quarters · filed 2023-02-09 | ||
| 2020-12-31 | $2.90M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-09 | $5.60M derived: sum of 2 quarters · filed 2023-02-09 | $8.00M derived: sum of 3 quarters · filed 2023-02-09 | $10.10M 10-K · filed 2023-02-09 | ||
| 2020-09-30 | $2.70M 10-Q · filed 2021-11-01 | $5.10M derived: sum of 2 quarters · filed 2021-11-01 | $7.20M 10-Q · filed 2021-11-01 | |||
| 2020-06-30 | $2.40M 10-Q · filed 2021-08-03 | $4.50M 10-Q · filed 2021-08-03 | ||||
| 2020-03-31 | $2.10M 10-Q · filed 2021-05-05 | |||||
| 2019-09-30 | $2.20M 10-Q · filed 2020-11-09 | $3.80M derived: sum of 2 quarters · filed 2020-11-09 | $4.90M 10-Q · filed 2020-11-09 | $6.46M derived: sum of 4 quarters · filed 2020-11-09 | ||
| 2019-06-30 | $1.60M 10-Q · filed 2020-08-03 | $1.61M 10-Q · filed 2019-07-29 | $2.70M 10-Q · filed 2020-08-03 | $2.74M 10-Q · filed 2019-07-29 | $4.26M derived: sum of 3 quarters · filed 2020-08-03 | $5.81M derived: sum of 4 quarters · filed 2020-08-03 |
| 2019-03-31 | $1.13M 10-Q · filed 2019-04-29 | $2.66M derived: sum of 2 quarters · filed 2019-04-29 | $4.21M derived: sum of 3 quarters · filed 2019-04-29 | $5.07M derived: sum of 4 quarters · filed 2019-07-29 | ||
| 2018-12-31 | $1.53M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-08 | $3.08M derived: sum of 2 quarters · filed 2019-02-08 | $3.94M derived: sum of 3 quarters · filed 2019-07-29 | $4.89M 10-K · filed 2019-02-08 | ||
| 2018-09-30 | $1.55M 10-Q · filed 2018-11-05 | $2.40M derived: sum of 2 quarters · filed 2019-07-29 | $3.35M 10-Q · filed 2018-11-05 | $4.12M derived: sum of 4 quarters · filed 2019-07-29 | ||
| 2018-06-30 | $854.00K 10-Q · filed 2019-07-29 | $1.80M 10-Q · filed 2019-07-29 | $2.56M derived: sum of 3 quarters · filed 2019-07-29 | $3.00M derived: sum of 4 quarters · filed 2019-07-29 | ||
| 2018-03-31 | $950.00K 10-Q · filed 2019-04-29 | $1.71M derived: sum of 2 quarters · filed 2019-04-29 | $2.14M derived: sum of 3 quarters · filed 2019-04-29 | $2.20M derived: sum of 4 quarters · filed 2019-04-29 | ||
| 2017-12-31 | $760.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-08 | $1.19M derived: sum of 2 quarters · filed 2019-02-08 | $1.25M derived: sum of 3 quarters · filed 2019-02-08 | $1.25M 10-K · filed 2019-02-08 | ||
| 2017-09-30 | $433.00K 10-Q · filed 2018-11-05 | $494.00K derived: sum of 2 quarters · filed 2018-11-05 | $494.00K 10-Q · filed 2018-11-05 | |||
| 2017-06-30 | $61.00K 10-Q · filed 2018-07-31 | $61.00K 10-Q · filed 2018-07-31 | ||||
| 2016-12-31 | $0.00 10-K · filed 2019-02-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |